https://www.selleckchem.com/products/hg-9-91-01.html This article reviews the acquisition protocols and image interpretation for F-fluorodeoxyglucose ( F-FDG) imaging with positron emission tomography (PET) applied to the evaluation of myocardial viability and inflammation. Cardiac PET with F-FDG provides essential information for the assessment of myocardial viability and inflammation and is usually combined with PET perfusion imaging using Rb or N-ammonia. Viable myocardium maintains glucose metabolism which can be detected via the uptake of F-FDG by PET imaging. The patient is prepared for viability imaging by shifting the metabolism of the heart to maximize the uptake of glucose and hence of F-FDG. Comparison of the F-FDG and myocardial perfusion images allows distinction between regions of the myocardium that are hibernating and thus may recover function with intervention, from those that are infarcted. Increased glucose utilization in the inflammatory cells also makes F-FDG a useful imaging technique in conditions such as cardiac sarcon in the inflammatory cells also makes 18F-FDG a useful imaging technique in conditions such as cardiac sarcoidosis. Here, suppression of normal myocardial uptake is essential for accurate image interpretation. 18F-FDG PET broadens the scope of information potentially available through a cardiac PET study. With careful patient preparation, it provides valuable insights into myocardial viability and inflammatory processes such as sarcoidosis. Immune checkpoint immunotherapies (ICI) are now approved for over 20 types of cancer and there are almost 6000 ongoing clinical trials investigating immuno-modulators as cancer therapies. This review investigated the effect of monoclonal antibody-based immune checkpoint immunotherapies when combined with cytokine therapy. We reviewed published clinical trial results from 2005 to 2020 for studies that used approved monoclonal antibody ICI in combination with the cytokines. Studies that met the